2023 Annual Meeting | S23 - Pain

Date Tuesday 04/25/23

Time 01:00 PM - 01:45 PM EST Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Scientific Platform Session

Moderator(s) Nathaniel M. Schuster, MD, Alyssa Lebel, MD

Topic(s) Pain

Learning Objectives A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes for question and answer with the author.

CME Available 0.75 CME credit

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Didactic

Event Timeline
01:00 PM - 01:12 PM EST	Abstract	001 - Peripheral myeloid cells control resolution of painful Chemotherapy-Induced Peripheral Neuropathy (CIPN) George Naratadam
01:12 PM - 01:24 PM EST	Abstract	002 - Novel Variants and Phenotypic Heterogeneity in Congenital Insensitivity to Pain Sinem Ovunc, MD
01:24 PM - 01:36 PM EST	Abstract	003 - Cilnidipine, a Novel N-Type Specific Calcium Channel Antagonist, Has Potent Activity at the Nav1.7 Sodium Channel, Which May Have Implications for Treatment of Certain Neuropathic Pain Conditions Andrew Sternlicht, MD

Faculty Disclosures
Sinem Ovunc, MD	Dr. Ovunc has nothing to disclose.
George Naratadam	Mr. Naratadam has nothing to disclose.
Andrew Sternlicht, MD	Dr. Sternlicht has received personal compensation for serving as an employee of Hotelrecovery, Inc. . Dr. Sternlicht has stock in Aisa Pharma. Dr. Sternlicht has received intellectual property interests from a discovery or technology relating to health care.
Fitnat Ulug	No disclosure on file
	No disclosure on file
Sema Saltik	No disclosure on file
Deniz Agirbaslo	No disclosure on file
Mehmet Seven	No disclosure on file
Aysel Kalayci Yigin	No disclosure on file
Nathaniel M. Schuster, MD	Dr. Schuster has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Schedule 1 Therapeutics. Dr. Schuster has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Averitas. Dr. Schuster has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ShiraTronics. Dr. Schuster has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Syneos. Dr. Schuster has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lohocla Research Corporation. Dr. Schuster has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Vertex. Dr. Schuster has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vectura Fertin. Dr. Schuster has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Rapport Therapeutics. Dr. Schuster has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Eli Lilly & Co. Dr. Schuster has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Averitas. Dr. Schuster has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Pain Medicine Journal. Dr. Schuster has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for Various Law Firms and the State of California. The institution of Dr. Schuster has received research support from Migraine Research Foundation. The institution of Dr. Schuster has received research support from UCSD Academic Senate. The institution of Dr. Schuster has received research support from NINDS 1 R01 AT012048-01A1. The institution of Dr. Schuster has received research support from NCCIH 5R00AT009466-04. The institution of Dr. Schuster has received research support from NCCIH U24 NS115714. The institution of Dr. Schuster has received research support from NIH/HEAL EN21-01.
Alyssa Lebel, MD	An immediate family member of Dr. Lebel has received personal compensation for serving as an employee of Stoke therapeutics. An immediate family member of Dr. Lebel has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for cytokinetics. An immediate family member of Dr. Lebel has stock in Stoke and Cytokinetics.